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Young womenAbstract Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disor-
der. It is associated with high prevalence of metabolic risk factors, but little is known about the
prevalence of metabolic syndrome (MS) and its components among Egyptian PCOS women. The
objective of the study was to determine the metabolic abnormalities among young Egyptian women
with PCOS and evaluate their relation with adiponectin gene (ADIPOQ) variants and body fat adi-
posity pattern.
Materials and methods: The present study included 80 PCOS women and 80 healthy women with
similar age and body mass index. All participants underwent clinical, anthropometric, biochemical,
ultrasonographic and adiponectin (ADIPOQ) gene 11391G>A (rs17300539) examinations.
Insulin resistance was assessed by the Homeostatic model assessment for insulin resistance
(HOMA-IR).
Results: MS was identiﬁed in 22.5% of PCOS women. The most prevalent MS components in
PCOS women were central obesity, decreased high-density lipoprotein cholesterol (HDL-C), andce; WC,
Insulin
368 M. Zaki et al.increased triglycerides (TG), blood pressure (BP) and fasting glucose levels. The study found asso-
ciation between ADIPOQ promoter variants 11391G>A and MS in PCOS women. Moreover,
multivariate logistic regression analysis showed association between abdominal fat accumulation
and IR in PCOS.
Conclusion: The prevalence of MS was signiﬁcantly higher in PCOS women than controls, and
central obesity and hypertension are risk factors for insulin resistance. Moreover, obesity plays a
key role in the development of PCOS and ADIPOQ 11391G>A gene variants showed association
with MS.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polycystic ovary syndrome (PCOS) as the most common
endocrinopathy among reproductive aged women is a major
health and economic burden. Depending on the criteria used
for its deﬁnition, the method used to deﬁne each criterion
and the study population, the prevalence of PCOS ranges
between 2.2% and 26% in various countries [1]. The ovarian
dysfunction syndrome encompasses a broad spectrum of
clinical signs and symptoms. Clinical manifestations include
menstrual irregularities, hyperandrogenism and infertility [2].
According to previous reports, insulin resistance, obesity and
dyslipidemia have commonly been described as associated with
PCOS [3]. These disorders are also the features of the so-called
metabolic syndrome (MS) or syndrome X, another cluster of
endocrine disturbances deﬁned by the World Health
Organization, the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) and the
International Diabetes Federation (IDF) guidelines [4].
Metabolic syndrome (MS) which is a common disorder
related to visceral obesity and insulin resistance (IR) is associ-
ated with atherosclerosis and cardiovascular (CV) disease [5,6].
The prevalence of MS is high, occurring in 23.7% of the USA
population over 20 years [7]. The prevalence also increases
with age, from 6.7% in the third decade to 43.5% in the 7th
decade [8,9]. The overall prevalence of MBS appears to be sim-
ilar between the USA and European countries with reported
rates of 23.5% in Spain and 23.9% in Portugal [10].
In Egypt, a cross-sectional observational study was con-
ducted on 1450 women visiting the outpatient clinic of Minia
University Maternity Hospital [11], included 620 middle-aged
fertile women with an intrauterine contraceptive device and
gave birth more than 2 years previously and 830 with primary
or secondary infertility reported that the prevalence of PCOS
in the fertile women was 14% (87/620) and 37.5% (311/830)
in the secondary infertile women.
MS is a combination of cardiovascular risk factors, includ-
ing dyslipidemia, impaired fasting glucose levels, abdominal
obesity and high blood pressure. Insulin resistance, as a major
defect in MS, appears to be a common linkage between these
coexisting abnormalities [12]. Since the anthropometric and
metabolic abnormalities found in PCOS overlap with the com-
ponents of MS [13,14], the issue regarding MS in women with
PCOS has generated tremendous interest. Diagnosis of MS
requires clinical and laboratory information that is grouped
into criteria. However, each institute deﬁnes the cut-off for
each criterion differently. Such difference would affect the
prevalence of MS, even within the same population [15].Recent studies have found a much higher prevalence of MS
in women with PCOS than in those without PCOS
[13,16,17]. According to estimates based on the US population,
the prevalence of MS in women with PCOS is approximately
43–46% [18,19].
The aim of the present study was to assess the metabolic
abnormalities among young Egyptian women with PCOS
and evaluate the inﬂuence of body fat adiposity pattern and
ADIPOQ gene variants and metabolic abnormalities.
2. Subjects and methods
All the procedures used in this study were in accordance with
the guidelines of the Helsinki Declaration on Human
Experimentations. The study was approved by local ethics
committee of the National Research Centre (No: 13176); the
purpose of the protocol was explained to both the patients
and control women, and written informed consent was
obtained from them before beginning the study.
This prospective case-control study included eighty
Egyptian women with PCOS between ages 20 and 35 years.
They were referred from different Obstetrics and Gynecology
centers to the National Research Centre Clinics between
2013 and 2014. All participated in the project entitled ‘‘Body
adiposity phenotypes, dietary intake, adiponectin gene
variants, metabolic markers and their signiﬁcance in obesity-
related diseases.’’
Eighty women controls of similar age and BMI of patients
were selected. All subjects were sedentary and were not partic-
ipating in any speciﬁc diet plan. The mean age of attaining
menarche in PCOS patients was 12.83 ± 1.11 years, and for
controls was 12.73 ± 1.35 years.
The diagnosis of PCOS was based on Rotterdam-PCOS
criteria [20].
According to these criteria, PCOS were diagnosed if at least
two of the following criteria were present: oligoamenorrhoea,
clinical or biochemical hyperandrogenism and PCO on
ultrasonography. Exclusion criteria: women with congenital
adrenal hyperplasia, androgen-secreting neoplasms, andro-
genic/anabolic drug use or abuse, Cushing’s syndrome,
syndromes of severe insulin resistance, thyroid dysfunction,
and hyperprolactinemia.
All control subjects underwent an ultrasonographic exami-
nation by a gynecologist, and women who had any pathologic
ﬁndings or polycystic ovaries were excluded from the study.
HOMA-IR cut-off was = 3.46 as insulin resistant [21].
MS was deﬁned using the deﬁnition of the 2001 National
Cholesterol Education Program Adult Treatment Panel III
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following abnormalities: waist circumference (WC) P88 cm;
fasting serum glucose of at least 110 mg/dL; fasting serum
triglycerides (TG) P150 mg/dL; serum high-density lipopro-
tein cholesterol (HDL-C) <50 mg/dL, and blood pressure
P130/85 mmHg. All subjects underwent a clinical examina-
tion where body weight, height, waist and hip circumferences,
and blood pressure were measured. All women met the
inclusion criteria, infertility P1 year and age <37 years.
2.1. Anthropometry and blood pressure
Anthropometric measurements included body weight, height,
mid upper arm, thigh waist and hip circumferences and skin-
fold thickness biceps, triceps and subscapular, suprailiac and
abdominal skin fold thickness were measured. All measure-
ments were taken 3 times on the left side of the body and
the mean of the 3 values was used. Body weight was measured
to the nearest 0.1 kg and height was measured to the nearest
0.1 cm. Height was measured with the patients standing with
their backs leaning against the stadiometer of the same scale.
BMI was calculated as weight in kilograms divided by height
in meters square (kg/m2). Waist circumference (WC) and hip
circumference (HC) were measured in cm using a plastic,
non-stretchable tailor’s tape. WC was measured with light
clothing at a level midway between the lower rib margin and
the iliac crest standing and breathing normally. HC was mea-
sured at the level at the widest circumference over the buttocks
(at the greater trochanter). Subsequently the waist hip ratio
(WHR) was calculated as WC divided by HC. Skin-fold thick-
ness was measured to the nearest mm, except for low values
(usually 5 mm or less) when it was taken to the nearest
0.5 mm. These readings were made at six sites on all subjects,
at the biceps, triceps, subscapular and supra-iliac areas, using
Holtain caliper (Ltd, Bryberian, Crymmych, Pembrokeshire).
The subscapular skinfold was taken at an angle of about 45’’
to the vertical. Biceps was measured at the level of the
mid-point between the acromion (lateral edge of the acromion
process) and the radius (proximal and lateral border of the
radius bone) on the mid-line of the anterior surface of
the arm, triceps (vertical fold, midway between acromion,
and olecranon processes on the posterior surface of the arm),
and the position of the suprailiac skinfold was the diagonal
fold just above the iliac crest even with the anterior axillary
line, abdominal skin fold was at 5 cm adjacent to the umbilicus
to the right side. Anthropometric measurements were obtained
according to standardized equipment and following the recom-
mendations of the International Biological Program [23].
Systolic and diastolic blood pressures (SBP and DBP) were
measured twice in the right arm in a sitting position after a
10 min rest period; using a mercury sphygmomanometer the
average of the two measurements was used for analysis.
Blood pressure was measured according to a standardized
operating procedure using a calibrated sphygmomanometer
and brachial inﬂation cuff (HEM-7200 M3, Omron
Healthcare, Kyoto, Japan). Hypertension was deﬁned accord-
ing to the guidelines set by the Joint National Committee on
Prevention, Evaluation and Treatment of High Blood
Pressure [24]: systolic blood pressure (SBP) > 140 mmHg or
diastolic blood pressure (DBP) > 90 mmHg or taking antihy-
pertensive medication.3. Laboratory measurements
Venous blood samples were collected by direct venipuncture
after an overnight (minimum 12 h) fast. Blood samples were
analyzed for glucose, triglyceride (TG), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C) and insulin. Serum
lipids (enzymatic methods) and plasma glucose (glucose
oxidase method) were assayed using the Hitachi 7060 C auto-
matic biochemistry analysis system. HDL-C and LDL-C were
measured directly.
Serum insulin was measured by monoclonal antibody-
based sandwich enzyme-linked immunosorbent assays
(ELISA) (Linco Research Inc., St. Charles, MO).
Insulin resistance index was calculated through surrogate
marker HOMA-IR. Insulin resistance (IR) was estimated
using the homeostasis model assessment index-insulin resis-
tance (HOMA-IR). With the determination of insulin and
glucose, it was possible to determine HOMA-IR using the fol-
lowing formula: [serum insulin · serum glucose/22.5].3.1. Transvaginal ultrasonography
A single transvaginal ultrasound scan was performed at a ran-
dom time (during the menstrual cycles) in subjects reporting
absent, irregular or regular periods. Scans were performed
by a single ultrasonographer using an Ultra Sonix RP ultra-
sound scanner equipped with a 9-MHz transvaginal transducer
(UltraSonix, Version 2.3.5, Vancouver, BC). Each ovary was
visualized and anatomic orientation with respect to the
utero-ovarian ligament was established. Ovaries were scanned
from the inner to outer margins in both the transverse and
sagittal planes.4. Molecular genotyping
Genomic DNA was extracted from peripheral blood leuco-
cytes using the salting out method. The Adiponectin
(ADIPOQ) gene promoter 11391G>A (rs17300539) single
nucleotide polymorphism (SNP) was genotyped [24]. The
polymerase chain reaction restriction fragment length poly-
morphism (PCR-RFLP) genotyping procedure was carried
out to the extracted genomic DNA. The following primers
were used (G-11391A): 50-CATC AGAA TGTG TGGC
TTGC-30 as forward and 50-AGAAGCAG CCTG GAGA
ACTG-30 as a reverse primer.
Each PCR reaction contained 25 ll ﬁnal volume consisting
of the following 250 ng genomic DNA, 200 uM dNTPS, 0.5
unit of DNA polymerase (DyNAZyme II, FINZYMES) and
20 pmol of each primer.
The thermocycling conditions consisted of initial denatura-
tion at 94 C for 10 min, followed by 40 cycles of 94 C for
30 s, 60 C for 30 s and 72 C for 30 s, then the ﬁnal extension
at 72 C for 10 min. The PCR products were digested with
MspI restriction endonuclease (Fermentas, Germany) at
37 C for 15 min. The products of the digest were then visual-
ized on a 2.5% agarose gel stained with ethidium bromide,
showing DNA fragments of 137 and 26 bps when the GG
genotype was detected and 163 bps of undigested PCR product
Table 1 Clinical and anthropometric characteristics of PCOS
and controls.
Parameters Group Mean ± SD P values
Age (years) PCOS 24.9 ± 2.4 .07
Controls 25.1 ± 3.4
BMI (kg/m2) PCOS 27.48 ± 4.30 .06
Controls 26.90 ± 3.75
Age at menarche (year) PCOS 12.83 ± 1.11 .07
Controls 12.73 ± 1.35
Systolic BP (mmHg) PCOS 135.71 ± 11.65 .05
Controls 114.74 ± 10.11
Diastolic BP(mmHg) PCOS 84.76 ± 9.28 .05
Controls 57.00 ± 73.07
MUAC (cm) PCOS 35.65 ± 6.37 .06
Controls 35.95 ± 6.67
WC (cm) PCOS 110.63 ± 17.43 .05
Controls 99.89 ± 17.63
HC (cm) PCOS 122.23 ± 17.00 .06
Controls 119.92 ± 17.29
WHR PCOS .82 ± .06 .04
Controls .83 ± .12
Biceps SF (mm) PCOS 22.67 ± 11.90 .07
Controls 24.66 ± 11.01
Triceps SF(mm) PCOS 29.82 ± 7.61 .08
Controls 31.12 ± 9.31
Subscapular SF(mm) PCOS 35.21 ± 9.37 .06
370 M. Zaki et al.when AA was detected. A pattern of 163, 137 and 26 bps was
obtained when GA genotype was detected.
5. Statistical analysis
All analyses were performed by using Statistical Product and
Service Solutions (SPSS) (version 13.0, spss Inc., Chicago,
IL, USA). Continuous variables were presented as
mean ± SD and analyzed using independent sample t-test
for normally distributed data or Mann–Whitney U-test for
skewed data. Categorical variables were expressed as propor-
tion (percentage) and analyzed by the chi-square test or
Fisher’s exact tests as appropriate. Multivariate logistic
regression was used to examine independent predictors of
MS and IR in PCOS. The results were expressed as odds ratio
(OR) with 95% conﬁdence interval (CI) and evaluated by two
sided p value. Baseline characteristics of the PCOS and
controls were evaluated by analysis of variance.
Pearson’s partial correlation coefﬁcients for body adiposity
indices and each measure of metabolic parameters were calcu-
lated, adjusted for BMI and age. Normal distribution was
tested using the Kolmogorov–Smirnov test. P< 0.05 was con-
sidered statistically signiﬁcant. Chi-square goodness of ﬁt test
was then utilized to evaluate Hardy–Weinberg equilibrium in
patient and control groups.Controls 33.19 ± 10.29
Abdominal SF(mm) PCOS 37.95 ± 7.83 .02
Controls 22.54 ± 8.65
Suprailiac SF(mm) PCOS 21.40 ± 9.79 .06
Controls 22.95 ± 7.74
PCOS, Polycystic Ovarian Syndrome; BMI, Body Mass Index; BP,
Blood Pressure; MUAC, Mid Upper Arm Circumference; WC,
Waist Circumference; HC; Hip Circumference; WHR, Waist to Hip
Ratio; SF, Skin Fold.
Table 2 Metabolic features in PCOS women and controls.
Parameters Group Mean ± SD P values
Glucose (mg/dl) PCOS 125.71 ± 68.85 .05
Controls 98.70 ± 52.95
Insulin (lU/ml) PCOS 23.03 ± 1.5 .03
Controls 13.06 ± 1.2
HOMA-IR PCOS 5.6 ± 1.4 .04
Controls 2.2 ± 1.2
Cholesterol (mg/dl) PCOS 208.70 ± 51.04 .05
Controls 188.38 ± 48.01
Triglycerides(mg/dl) PCOS 140.09 ± 93.31 .01
Controls 104.05 ± 48.03
HDL-C (mg/dl) PCOS 43.22 ± 14.93 .02
Controls 49.57 ± 14.65
LDL-C (mg/dl) PCOS 137.30 ± 28.44 .03
Controls 119.10 ± 29.45
PCOS, Polycystic Ovarian Syndrome; HOMA-IR Homeostatic
Model Assessment for Insulin Resistance; HDL-C, High Density
Lipoprotein Cholesterol; LDL-C, Low Density Lipoprotein
Cholesterol.6. Results
The mean age of women in the control group (25.1 ± 3.4 year)
was similar to the mean age of the PCOS group
(24.9 ± 2.4 year). The clinical and anthropometric characteris-
tics of women with PCOS and controls are given in Table 1.
The mean BMI of the two groups ranged between 25 and
30 kg/m2, and there was no signiﬁcant difference between the
two means. But different patterns of fat distribution were seen
between the two groups.
Patients with PCOS had higher waist circumference, waist
to hip ratio, abdominal skin-fold thickness and blood pressure
level compared to normal controls of the same age and BMI
(P< 0.05).
Metabolic features of PCOS patients were compared with
the controls (Table 2). The PCOS patients showed signiﬁcantly
higher levels of serum fasting glucose, insulin, HOMA-IR, TG,
and LDL and lower levels of HDL-C than the matched age
and BMI controls.
In PCOS women, increased waist circumference (>88 cm)
was found in 96.25% of women, reduced HDL-C (<50 mg/dl)
was found in 75% of women and increased TG level was found
in women (63.75%) and increased blood glucose was found in
33.75% of PCOS women while in BMI-matched controls,
increased waist circumference was found in 37.5% of women,
reduced HDL-C was found in 25% of women, increased TG
level was found in women (12.5%) and increased blood
glucose in 13.75% (p< .05) (Fig. 1).
Pearson’s partial correlation coefﬁcients for body adiposity
indices, adjusted for age and BMI and the metabolic parame-
ters were evaluated (Table 3). Although there was no statisti-
cally signiﬁcant correlation between body fat % and
metabolic markers, the WC, WHR and abdominal skin fold
thickness showed a signiﬁcant positive correlation with meta-
bolic parameters including the systolic and diastolic bloodpressure, fasting glucose, TG and negative correlation with
HDL-C levels.
Table 4 shows multivariate logistic regression performed to
examine the predictors of IR in women with PCOS. For
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CI 1.437–1.618) and WCP 88 cm (OR: 1.72, 95% CI 1.558–
1.948) and increased blood pressures (>130/>85 mm Hg)
(OR: 1.52, 95% CI 1.658–1.977) were risk factors for IR in
PCOS women, independent of obesity level and age.
The frequency of the ADIPOQ11391GOA variants GG,
GA and AA was not deviated from the expected proportions
of genotypes in the population predicted by the Hardy–
Weinberg equilibrium (Table 5), the genotype distributions
at position 11391 were signiﬁcantly different between the
PCOS groups with and without MS.
Among PCOS with MS, the frequency of 11391GG was
signiﬁcantly lower compared to those without MS (55.55 vs.
72.58%) (p= .02). Moreover, frequency of the 11391A alle-
les was signiﬁcantly different between the two groups
(p= 0.04) and the carriers of the 11391A allele were more
frequent among PCOS with MS (27.77 vs. 13.11%).7. Discussion
The results of our study show the frequency of MS in repro-
ductive age women with PCOS to be 20.5% which is similar
to the prevalence of MS in other ethnicities and races diag-
nosed with PCOS [17]. However in some ethnic groups, such
as the American population, the prevalence is higher than
our study, at about 40% [19,25]. These differences are possibly
related to factors such as age, diet and lifestyle that cause
increased waist circumferences, hypertriglyceridemia and
reduced HDL cholesterol levels as important components for
MS.
The prevalence of MS in women with PCOS is less common
in southern Italy compared with women in the USA, using the
most used method to assess the presence of metabolic syn-
drome (the ATP-III criteria), the prevalence of MS was
8.2% in Italy [18] than in 43–46% of patients in the USA
[19,25], and all diagnostic criteria were less common in
Italian PCOS, the main difference was in the lower prevalence
of hypertriglyceridemia (increased triglycerides were present in
only 9.3% of patients).
In another study, the quantity of saturated fat in the diets
of USA women was almost double than that of Italian women
[26].
The prevalence of MS in the Egyptian PCOS was 22.5%. In
the current study women with PCOS had markedly higher
levels of HOMA-IR score, serum triglycerides and blood
pressure and lower HDL-C levels as compared to age-BMI-
matched healthy women.
The prevalence of MS in obese women with PCOS was
approximately twofold increase compared with non-obese
women. Since most of the women with PCOS (38–88%) are
overweight or obese, therefore there is little doubt that adipos-
ity plays an important role in development and maintenance of
PCOS and strongly inﬂuences the severity of both its clinical
and endocrine characteristics in numerous women [27].
Obesity appears to be an independent factor for MS abnormal-
ities [28,29] and our results are in accordance with the idea that
as BMI increases the prevalence of high WC and hypertension
increases. Nevertheless, fasting serum glucose levels and the
rates of dyslipidemia showed no statistically signiﬁcant differ-
ence among the BMI groups, an important ﬁnding corroborat-
ing the relevance of screening for MS and other cardiovascularrisk factors in all women with PCOS, regardless of obesity.
The results of this study have conﬁrmed the high frequency
of MS and its components, in particular a decreased HDL-C
level and an increased TG level in women with PCOS.
Thus, these women are at increased risk of diabetes mellitus
and cardiovascular disease (CVD). Therefore, it is important
to screen all women with PCOS for cardiovascular risk factors.
Recognition and clinical management of this high-risk group
are important to prevent CVD and associated mortality in
the population.
Polycystic ovaries were diagnosed by pelvic or intravaginal
sonography according to the Rotterdam conference criteria
[30].
The consequences of the polycystic ovary syndrome
extended beyond the reproductive axis; as women with
PCOS are at substantial risk for the metabolic syndrome.
Also, previous studies indicated that 30–40% of women
with PCOS have impaired glucose tolerance, and as many as
10% have type 2 diabetes by their fourth decade [31,32].
A meta-analysis supported a greater prevalence of glucose
intolerance (IGT), type 2 diabetes (DM2) and the metabolic
syndrome in women with PCOS as compared with women
without PCOS. The odds of metabolic disturbance were two
to four times as high in PCOS women [33]. The predisposition
of PCOS women to various metabolic disturbances, including
obesity, IGT, atherogenic dyslipidaemia and hypertension,
increased in the long-term risk of DM2 and cardiovascular dis-
ease (CVD), which indicated that PCOS carried signiﬁcant
public health implication. Recent evidence also indicated more
frequent CVD death in women with PCOS [34].
An economic evaluation estimated that 40% of the eco-
nomic costs of PCOS can be attributed to DM2 in the USA,
highlighting the need for prevention of long term complica-
tions through appropriate screening diagnosis and intervention
for PCO [34].
Clinical hyperandrogenism was deﬁned as the presence of
hirsutism (Ferriman–Gallwey) score P6 with no oral contra-
ceptive pills were used within three months. Biochemical
hyperandrogenism was present if testosterone >2.8 nmol/L
or androgen >10.8 nmol/L, which were the normal range of
95% percentile in the population in our laboratory. PCO
was deﬁned as the presence of at least one ovary with 12 or
more follicles measuring 2–9 mm in diameter. The relationship
between hyperandrogenemia and metabolic abnormalities is
controversial. Apridonidze et al. [19], described a higher preva-
lence of hyperandrogenemia in women with concomitant
PCOS and MS, other study concluded that DHEAS correlated
inversely with arterial structure, suggesting possible cardio-
protective effects of endogenous DHEAS in women with
PCOS [35].
However, other studies from Dokras et al. [13], and Cheung
et al. [17], all failed to demonstrate any signiﬁcant differences
in serum concentrations in total testosterone and androgen
between those PCOS women with or without MS. Therefore,
it appeared that hyperandrogenemia, by itself, may not directly
contribute to the development of MS in women with PCOS.
Homeostatic Model Assessment score (HOMA), is a good
indicator of insulin resistance (IR). This HOMA score was sig-
niﬁcantly higher in the PCOS subgroups compared to controls,
similar to the ﬁndings of Chae et al. [36]. The increase of IR
was explained by higher central obesity in the present PCO
group similarly as reported by Cosar et al. [37]. Dyslipidemia
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Figure 1 Frequency distribution of the metabolic syndrome components in women with PCOS and normal controls.
Table 3 Pearson’s partial correlation coefﬁcient for measures
of adiposity and metabolic parameters in PCOS women.
WC WHR Abdominal skin fold
thickness
Body
fat %
HOMA-
IR
0.35
(0.02)
0.34
(0.03)
0.35 (0.05) 0.055
(0.45)
FB
glucose
0.65
(0.05)
0.51
(0.05)
0.38 (0.01) 0.065
(0.55)
Systolic
BP
0.65
(0.04)
0.35
(0.03)
0.45 (0.05) 0.155
(0.06)
Diastolic
BP
0.65
(0.04)
0.35
(0.03)
0.45 (0.05) 0.175
(0.07)
TG 0.65
(0.04)
0.35
(0.03)
0.45 (0.05) 0.153
(0.53)
HDL-C 0.65
(0.04)
0.35
(0.03)
0.45 (0.05) 0.075
(0.63)
Data are presented with correlation coefﬁcient (P value).
PCOS, Polycystic Ovarian Syndrome; FBG, Fasting Blood Glu-
cose; BP, Blood Pressure; TG, Triglycerides; HDL-C, High Density
Lipoprotein Cholesterol; WC, Waist Circumference; WHR, Waist
to Hip Ratio.
Table 4 Predictors of IR in Egyptian PCOS by using
multivariate logistic regression analysis.
Risk factor OR* 95.0% CI P
IR WHR> 0.85 cm 1.62 1.437–
1.618
.001
WCP 88 cm 1.72 1.558–
1.948
.001
High-blood pressure (>130/
>85 mmHg)
1.52 1.658–
1.977
.001
IR, Insulin Resistance; WHR, Waist to Hip Ratio; WC, Waist
Circumference.
* Age and BMI adjusted odds ratio.
Table 5 Distribution of the ADIPOQ 11391G>A geno-
types and alleles in PCOS with and without MS.
Genotype/allele MS(+) (n= 18) MS() (n= 62) P
n (%) n (%)
GG 10 (55.55) 45 (72.58) .02
GA 6 (33.33) 17 (27.41)
AA 2 (11.11 0 (0)
G 26 (72.22) 107 (86.29) .04
A 10 (27.77) 17 (13.71)
MS(+): with metabolic syndrome.
MS(): without metabolic syndrome.
372 M. Zaki et al.is one of the common metabolic abnormalities in PCOS, which
is associated with IR and hyperinsulinemia, which was also
noted in the present study.
Previous studies reported that in women with obesity and
infertility as well as anovulatory women have signiﬁcantly
more subcutaneous abdominal fat and higher fasting insulin
levels and the same amount of intra-abdominal fat compared
with ovulatory women with the same BMI [38]. A possibleexplanation for an increased volume of subcutaneous abdom-
inal fat in anovulatory women with obesity could be provided
by the concept of a critical intra-abdominal fat threshold. This
concept suggests that during constant high calorie food con-
sumption, storage of fat in intra-abdominal fat reaches a point
of saturation, after which fat is shunted to the subcutaneous
fat compartments [39]. With increased accumulation of subcu-
taneous abdominal fat, inﬂammatory changes and increase in
adipocyte size occur. Fat is then shunted from subcutaneous
abdominal fat to the liver and skeletal muscle which con-
tributes to an increase of IR [40,41]. In this study the
prevalence of different elements of the metabolic syndrome
in Egyptian PCOS women with fat accumulation was signiﬁ-
cantly higher than those without abdominal fat accumulation
(waist to hip ratio >.85).
It has been demonstrated that a high percentage of PCOS
patients even without general obesity have excessive visceral
fat accumulation [42]. It has been suggested that increased
accumulation of fat in the abdominal site of PCOS women
may induce adipose tissue dysfunction [43] and increase IR
[44,45] and hyperandrogenism [46], both of which are common
features of PCOS.
In addition, other studies reported that resumption of ovu-
lation during weight loss is associated with a decrease in fast-
ing insulin and free testosterone levels [47,48] and associated
with improvement in IR, and lower insulin levels which leads
to less androgen [49]. Lower free androgen levels in the long
term, limits the amount of abdominal fat accumulation [50,51].
Although the presence of MS has been linked to decreased
adiponectin values, the association of ADIPOQ variants with
MS and its components remains vague [52]. The effect of the
ADIPOQ gene on the risk of obesity and MS may vary
Metabolic abnormalities in young Egyptian women with polycystic ovary syndrome 373according to ethnicity, age and the degree of obesity across
populations [53]. Some studies indicated that ADIPOQ vari-
ants may contribute to MS and its components [54], whereas
other reports point to the limited impact of ADIPOQ gene
on MS parameters [55]. In this study we found association
between ADIPOQ promoter variants 11391G>A and MS
in young Egyptian women with PCOS.
In conclusion, the prevalence of MS was signiﬁcantly higher
in PCOS women than controls, and central obesity and hyper-
tension are risk factors for insulin resistance. Moreover,
obesity plays an important role in the development of PCOS
and ADIPOQ11391G>A gene variants is associated with
MS among young Egyptian women with PCOS.
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